Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
Rain Therapeutics Inc. (NasdaqGS: RAIN) is scheduled to present at the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. CEO Avanish Vellanki will lead the presentation on September 30, 2021, at 10:00 a.m. ET, which can be accessed via a webcast link or through Rain's website. The event aims to showcase Rain’s advancements in precision oncology therapeutics, including their lead product candidate, milademetan, a small molecule oral inhibitor targeting MDM2. A replay will be available on their website for 30 days after the event.
- None.
- None.
Insights
Analyzing...
NEWARK, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference being held virtually September 27-30, 2021.
Additional details can be found below:
Date: Thursday, September 30, 2021
Time: 10:00 a.m. ET
Location: Webcast Link – or at the company’s website (click here)
A replay of the presentation will be available by visiting the "Events & Presentations" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Media Contact
Jordyn Temperato
LifeSci Communications
+1.646.876.5196
jtemperato@lifescicomms.com
FAQ
When is Rain Therapeutics presenting at the Cantor Fitzgerald Virtual Global Healthcare Conference?
Who is the CEO of Rain Therapeutics?
What is the focus of Rain Therapeutics' presentation?
How can I access the Rain Therapeutics presentation?
Will there be a replay of the Rain Therapeutics presentation?
